p53 mediates PEDF‑induced autophagy in human umbilical vein endothelial cells through sestrin2 signaling.

Publisher: D. A. Spandidos Country of Publication: Greece NLM ID: 101475259 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1791-3004 (Electronic) Linking ISSN: 17912997 NLM ISO Abbreviation: Mol Med Rep Subsets: MEDLINE

Original Publication: Athens, Greece : D. A. Spandidos

Autophagy/*genetics ; Eye Proteins/*genetics ; Human Umbilical Vein Endothelial Cells/*drug effects ; Nerve Growth Factors/*genetics ; Nuclear Proteins/*genetics ; Serpins/*genetics ; Signal Transduction/*genetics ; Tumor Suppressor Protein p53/*genetics; Adaptor Proteins, Signal Transducing/genetics ; Adaptor Proteins, Signal Transducing/metabolism ; Autophagy/drug effects ; Cell Cycle Proteins/genetics ; Cell Cycle Proteins/metabolism ; Eye Proteins/metabolism ; Eye Proteins/pharmacology ; Gene Expression Regulation ; Human Umbilical Vein Endothelial Cells/cytology ; Human Umbilical Vein Endothelial Cells/metabolism ; Humans ; Microtubule-Associated Proteins/genetics ; Microtubule-Associated Proteins/metabolism ; Nerve Growth Factors/metabolism ; Nerve Growth Factors/pharmacology ; Nuclear Proteins/antagonists & inhibitors ; Nuclear Proteins/metabolism ; Phosphorylation/drug effects ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Ribosomal Protein S6 Kinases, 70-kDa/genetics ; Ribosomal Protein S6 Kinases, 70-kDa/metabolism ; Sequestosome-1 Protein/genetics ; Sequestosome-1 Protein/metabolism ; Serpins/metabolism ; Serpins/pharmacology ; TOR Serine-Threonine Kinases/genetics ; TOR Serine-Threonine Kinases/metabolism ; Tumor Suppressor Protein p53/antagonists & inhibitors ; Tumor Suppressor Protein p53/metabolism

Autophagy is a conserved catabolic process by which cytoplasmic components are delivered into lysosomes for degradation. Pigment epithelium‑derived factor (PEDF) has been reported to be associated with autophagy and can induce p53 expression; however, the mechanism relating PEDF with autophagy in endothelial cells remains poorly understood. The present study aimed to investigate the association between the PEDF‑p53‑sestrin pathway and autophagy in human umbilical vein endothelial cells (HUVECs). PEDF‑induced autophagy was examined by fluorescence microscopy and western blot analysis. p53 small interfering (si)RNA and sestrin2 siRNA were constructed and transfected into HUVECs prior to PEDF treatment. The protein expression levels of microtubule‑associated protein light chain 3 (LC3) I, LC3 II and p62 were evaluated by western blot analysis, and the mRNA expression levels of p53 and sestrin2 were determined using reverse transcription‑quantitative polymerase chain reaction analysis. The regulation of mechanistic target of rapamycin (mTOR) was reflected by p70S6 kinase (p70S6K) and eukaryotic translation initiation factor 4E‑binding protein 1 (4E‑BP1) protein expression levels, as determined by western blot analysis. PEDF could induce HUVEC autophagy by sequentially inducing p53 and sestrin2 expression, as observed by fluorescence microscopy and western blot analysis. Conversely, the induction of sestrin2 by PEDF was eliminated by p53 siRNA. In addition, p53 siRNA and sestrin2 siRNA could attenuate PEDF‑induced HUVEC autophagy. Inhibition of mTOR may be the mechanism responsible for PEDF‑induced autophagy; as p70S6K and 4E‑BP1 phosphorylation levels were significantly upregulated in p53 siRNA‑treated and sestrin2 siRNA‑treated groups. The findings of the present study indicated that PEDF may trigger autophagy in HUVECs by inducing p53 and sestrin2 expression, and inhibiting mTOR expression; these findings may contribute to the improved understanding of diseases, including cancer and atherosclerosis.

Methods. 2001 Dec;25(4):402-8. (PMID: 11846609)
Cardiovasc Res. 2007 Nov 1;76(2):213-23. (PMID: 17651710)
Cell. 2008 Aug 8;134(3):451-60. (PMID: 18692468)
Nephrol Dial Transplant. 2009 May;24(5):1397-406. (PMID: 19042927)
J Cell Mol Med. 2009 Sep;13(9B):3687-98. (PMID: 19298526)
Cell Cycle. 2009 May 15;8(10):1571-6. (PMID: 19377293)
Cell Cycle. 2009 May 15;8(10):1467. (PMID: 19411829)
Br J Pharmacol. 2011 Sep;164(2b):731-42. (PMID: 21418191)
J Natl Cancer Inst. 2012 Jun 20;104(12):899-905. (PMID: 22572994)
Cancer Res. 2012 Oct 15;72(20):5165-73. (PMID: 22902412)
Cancer Res. 2013 Jan 1;73(1):160-71. (PMID: 23149913)
Nat Rev Cancer. 2013 Apr;13(4):258-71. (PMID: 23486238)
Int J Cancer. 2013 Nov;133(9):2102-12. (PMID: 23629809)
Cancer Discov. 2014 Aug;4(8):905-13. (PMID: 24875860)
J Endocrinol. 2014 Sep;222(3):R129-39. (PMID: 24928938)
Apoptosis. 2016 Jan;21(1):60-8. (PMID: 26519036)
Autophagy. 2015;11(12):2375-6. (PMID: 26565689)
Cancer Lett. 2016 Mar 1;372(1):89-100. (PMID: 26739061)
Cancer Res. 2016 Apr 15;76(8):2265-76. (PMID: 26921338)
J Hypertens. 2016 Jul;34(7):1380-8. (PMID: 27115339)
Blood. 2016 Sep 22;128(12):1614-24. (PMID: 27480114)
Oncotarget. 2016 Sep 27;7(39):63242-63251. (PMID: 27557517)
Oncotarget. 2016 Oct 25;7(43):69688-69702. (PMID: 27626169)
Crit Rev Oncol Hematol. 2016 Dec;108:1-12. (PMID: 27931828)
J Hematol Oncol. 2017 Mar 9;10(1):67. (PMID: 28279189)
Cell. 2017 Mar 9;168(6):960-976. (PMID: 28283069)
J Cell Physiol. 2018 Mar;233(3):2434-2443. (PMID: 28776671)
Int J Biochem Cell Biol. 2018 Mar;96:90-95. (PMID: 29355754)
Br J Ophthalmol. 2018 Jun;102(6):848-854. (PMID: 29478030)
Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):1133-1141. (PMID: 29509267)
Biomolecules. 2018 Mar 21;8(2):. (PMID: 29561758)
BMC Cancer. 2018 Mar 27;18(1):342. (PMID: 29587684)
Oncol Lett. 2018 Jun;15(6):9333-9338. (PMID: 29844830)
Lab Invest. 2018 Nov;98(11):1423-1437. (PMID: 30089855)

0 (Adaptor Proteins, Signal Transducing)
0 (Cell Cycle Proteins)
0 (EIF4EBP1 protein, human)
0 (Eye Proteins)
0 (MAP1LC3A protein, human)
0 (MAP1LC3B protein, human)
0 (Microtubule-Associated Proteins)
0 (Nerve Growth Factors)
0 (Nuclear Proteins)
0 (RNA, Small Interfering)
0 (SESN2 protein, human)
0 (SQSTM1 protein, human)
0 (Sequestosome-1 Protein)
0 (Serpins)
0 (Tumor Suppressor Protein p53)
0 (pigment epithelium-derived factor)
EC 2.7.1.1 (MTOR protein, human)
EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
EC 2.7.11.1 (TOR Serine-Threonine Kinases)

Date Created: 20190608 Date Completed: 20200106 Latest Revision: 20211204

20221213

PMC6625384

10.3892/mmr.2019.10319

31173218